Pharmaceuticals APAC News & Press Release Distribution

Nippon Express (UK) Receives IATA CEIV Pharma Certification for Its Facility in Heathrow Airport Suburb

TOKYO, April 25, 2023 /PRNewswire/ -- Nippon Express (UK) Ltd. (hereinafter "NXUK"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been awarded IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association (I...

2023-04-25 15:00 1917

Biotech firm Gene Solutions: A promising picture for multi-cancer early detection in Southeast Asia

HO CHI MINH CITY, Vietnam, April 25, 2023 /PRNewswire/ -- In January 2023, Vietnam's Medical Genetics Institute & Gene Solutions published their research paper on Cancer Investigation:Clinical validation of a ctDNA-based assay for multi-cancer detection: an interim r...

2023-04-25 12:00 1905

Biotech firm Gene Solutions: A promising picture for multi-cancer early detection in Southeast Asia

Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal

SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- The research results of Daewoong Pharmaceutical's SGLT-2 inhibitor new drug, 'Envlo', have been internationally acknowledged. On April 4, Daewoong Pharmaceutical (CEO Seng-ho Jeon and Chang-jae Lee) announced that the efficacy and safety evalu...

2023-04-24 14:53 2080

Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical Trial of BBM-H901

SHANGHAI, April 24, 2023 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced today the completion of patient dosing in its Phase III Registrational Clinical Trial (CTR20212816) of BBM-H901, a gene therapy for Hemophilia ...

2023-04-24 10:23 2101

SCG Cell Therapy to Present Late-Breaking Data at the International Society for Cell & Gene Therapy (ISCT) Highlighting Promising Antitumor and Antiviral Activities of SCG101 in Treating HBV-Related Hepatocellular Carcinoma

SINGAPORE, April 24, 2023 /PRNewswire/ -- Singapore based SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that late-breaking data from the company's TCR-T therapy pipeline...

2023-04-24 10:00 2171

Everest Medicines Launches Nefecon in China's Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy

SHANGHAI, April 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that Nefecon, the first-in-disease treatment fo...

2023-04-24 07:44 2369

LTS expands into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business

ANDERNACH, Germany, April 21, 2023 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"), Oral Thin Films ("OTF") and Micro Array Patches ("MAP") anno...

2023-04-21 00:00 2371

BioMed Technology Funded by Alibaba Hong Kong Entrepreneurs Fund, Gobi and TIMC to Realise Precision and Personalised Gut Microbiome Management for Wellness

HONG KONG, April 20, 2023 /PRNewswire/ -- BioMed Technology Holdings Limited (BioMed),Hong Kong's leading microbiome startup, has raised USD 2 million in its latest oversubscribed seed round from Alibaba Hong Kong Entrepreneurs Fund (AEF), Gobi Partners GBA and The International Medical Co. Ltd. ...

2023-04-20 16:15 3665

BioMed Technology Funded by Alibaba Hong Kong Entrepreneurs Fund, Gobi and TIMC to Realise Precision and Personalised Gut Microbiome Management for Wellness

Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 20, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-20 08:00 3728

Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line

SAN DIEGO, April 19, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company's high pot...

2023-04-19 20:05 1789

Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China

SHANGHAI, April 19, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that it has signed a Memorandum of Understandin...

2023-04-19 08:12 2336

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

GUANGZHOU, China, April 18, 2023 /PRNewswire/ -- April 15, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") announced that the Company received IND approval for its second product in the pipeline, a T-cell redirection therapy for the treatment of EBV-positive lymphoma. A week prior to this, t...

2023-04-18 19:03 3168

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration

- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening SEOUL, South Korea and NOTTINGHAM, England, April 18, 2023 /PRNewswire/ -- Daewoong Pharmaceuti...

2023-04-18 17:16 2353

West Korea Announces Ready Pack™ Containment Solution Extension at COPHEX 2023

SEOUL, South Korea, April 18, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (West), a global leader in innovative solutions for injectable drug administration, today announced the extension of its complete containment solution, Ready Pack™, in South Korea at...

2023-04-18 10:00 1805

West Korea Announces Ready Pack™ Containment Solution Extension at COPHEX 2023

Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease

PRINCETON, N.J., April 18, 2023 /PRNewswire/ -- EMJ Nephrology interviewed two World-renowned experts in nephrology and cardiology,George Bakris and Faiez Zannad, regarding the challenges of treating uncontrolled hypertension (uHTN) in patients with advanced chronic kidney disease (CKD), a large ...

2023-04-18 08:00 1920

Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...

2023-04-18 08:00 2549

Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-18 08:00 2450

Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting

Promising anti-tumor activity reported for C-CAR031, a novel Glypican 3 (GPC3)-targeting cell therapy designed by AstraZeneca SHANGHAI, April 18, 2023 /PRNewswire/ -- Shanghai Cellular Biopharmaceutical Group Ltd. (the Company, or Shanghai Cellular Bio), a company engaged in the drug development...

2023-04-18 04:15 1752

Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended31 March 2023 (Q1 2023). All figures are in AUD$ unless otherwise st...

2023-04-17 18:15 2053

Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023

SUZHOU, China, April 17, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) were presented as a poster at the Late-Breaking Research session of the AACR Annual Meeting 2023 (AACR 2023). The AACR Annual Meet...

2023-04-17 14:01 1895